All News

If a car had a 50% chance of crashing, I would never let my son in it. With a hereditary cancer syndrome, though, there's no safety feature to lessen the odds. The mutation is simply there, or it isn't.

Dr. Gregory Tiesi discusses TAMP, a targeted therapy that delivers chemotherapy directly to pancreatic tumors with fewer side effects.

A kidney cancer survivor shares how a decade of breakthroughs in immunotherapy and targeted research transformed a death sentence into a life saved.

CTIM-76 has received FDA fast track designation for platinum-resistant ovarian cancer, a step aimed at accelerating development for patients with few options.

New research shows adults over 80 with early-stage lung cancer can achieve surgical outcomes and quality of life comparable to younger patients.

Cogent submitted an FDA application for bezuclastinib after the phase 3 PEAK trial shows improved progression-free survival in patients with previously treated GIST.

Although I know better, I gardened in a sleeveless shirt and ended up with a poison ivy rash on my lymphedema limb. This time, I was lucky. Hopefully I will follow my own advice and avoid tempting fate next time.

Nurse Bridget Hopkins shares how she navigates metastatic breast cancer through second opinions, "YOLO" trips and the power of advanced care planning.

The phase 3 EMERALD-3 trial shows Imfinzi and Imjudo plus Lenvima and embolization improved progression-free survival in unresectable liver cancer.

A new study shows Signatera ctDNA testing may identify older patients with ER+/HER2- breast cancer who can manage their care without invasive surgery.

A study found blood-based genomic testing can be completed in 27 hours, giving patients with cancer faster treatment decisions.

Eleven years with Stage 4 breast cancer, all on the first line of treatment. It isn’t chronic, but what is it?

Multiple myeloma survivor JP Kealy and wife Annamarie share how to avoid cancer burnout and why this journey is a marathon, not a sprint.

A phase 3 trial finds anbenitamab and docetaxel improve response rates in patients with HER2-positive breast cancer and offer a safer delivery.

A couple opens up about navigating cancer care, advocating for themselves and balancing caregiver responsibilities with self-care.

New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients with lung cancer.

Author and multiple myeloma survivor Jonathan Gluck shares how an unexpected diagnosis reshaped his identity and approach to living with uncertainty.

The 49th Annual Miami Breast Cancer Conference recently hosted a cornerstone event for the advocacy community: the CURE Educated Patient® Breast Cancer Summit.

Dr. Susan MacDonald, a urologist who has been diagnosed with stage 4 breast cancer, launches a new vlog series for CURE, “Demystifying the Darkness.”

Eight patients with NSCLC treated with ateganosine plus Libtayo had over 2-year survival after prior therapies, based on phase 2 THIO-101 trial data.

Author and survivor Parul Somani shares how patients with breast cancer can find peace of mind when clinical certainty is missing.

Early detection and grade-based care help manage immunotherapy toxicities, with tailored approaches for skin, gastrointestinal and cardiac side effects.

New NCCN guidelines highlight personalized combo treatments and new options to help patients with advanced kidney cancer live longer, better lives.

A couple shares how caregiving, communication and perspective shaped their life after liver cancer.

AI is being used across cancer care for prevention, diagnosis, treatment, survivorship and end-of-life support, improving efficiency while posing deskilling and cognitive risks.

Amanda shares advice on resilience, self-advocacy and finding strength while navigating cancer survivorship and chronic GVHD.

FDA fast tracked ZW191 for platinum-resistant ovarian cancer, aiming to speed development of a potential new option for patients with limited treatments.

Black patients with early-stage lung cancer were less likely to receive curative treatment than White patients, despite all having Medicare coverage, study finds.